Study EGF107671 - a phase II study of lapatinib plus topotecan or lapatinib plus capecitabine in the treatment of recurrent brain metastases from ErbB2 [HER2]-positive breast cancer following cranial radiotherapy.

Trial Profile

Study EGF107671 - a phase II study of lapatinib plus topotecan or lapatinib plus capecitabine in the treatment of recurrent brain metastases from ErbB2 [HER2]-positive breast cancer following cranial radiotherapy.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 20 Oct 2015

At a glance

  • Drugs Lapatinib (Primary) ; Capecitabine; Topotecan
  • Indications Advanced breast cancer; Brain metastases
  • Focus Pharmacogenomic; Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 01 Dec 2011 Results published in the Journal of Neuro-Oncology.
    • 23 Feb 2010 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top